1. Introduction; 2. Status of the epidemic: India's specificities; 3. Aids - a public health problem; 4. Main public health measures; 5. The Indian pharmaceutical industry - from a "Strong" IPR system to a "Weak" IPR system; 6. Arv production in India: the main players cipla and ranbaxy; 7. Access of Indian patients to arv treatments today and tomorrow; 8. Conclusion.